SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-008306
Filing Date
2023-03-16
Accepted
2023-03-16 07:45:40
Documents
14
Period of Report
2023-03-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fusn-20230316.htm   iXBRL 8-K 59433
2 EX-99.1 fusn-ex99_1.htm EX-99 223242
3 GRAPHIC img92740539_0.jpg GRAPHIC 2668
  Complete submission text file 0000950170-23-008306.txt   428537

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fusn-20230316_pre.xml EX-101.PRE 11545
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fusn-20230316.xsd EX-101.SCH 2474
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fusn-20230316_lab.xml EX-101.LAB 18645
8 EXTRACTED XBRL INSTANCE DOCUMENT fusn-20230316_htm.xml XML 4875
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 23737163
SIC: 2836 Biological Products, (No Diagnostic Substances)